Informação sobre produto
- 1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]4-piperidinyl]-2H-benzimidazol-2-one
- 1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
- 2H-benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]-4-piperidinyl]-
- 3-[1-[[4-(7-phenyl-3H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
Akti-1/2 is a potential anticancer agent that inhibits growth and induces apoptosis in cancer cells. Akti-1/2 has been shown to induce autophagy, which is the process by which cells degrade cellular components, leading to increased mitochondrial membrane potential and inhibition of cell death. Akti-1/2 also activates cyclin D2 and MCL-1 protein expression, which are important for cell cycle progression. Akti-1/2 has inhibitory properties against the proliferation of cancer cells in vitro and synergistic effects with chemical inhibitors. This drug may be useful for the treatment of eye disorders such as macular degeneration or retinitis pigmentosa.
Propriedades químicas
Consulta técnica sobre: 3D-FA17246 Akti-1/2
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.